INSIGHTS ON CELL & GENE THERAPY LOGISTICS

• Securing Today’s Biomanufacturing Supply Chain Using Transformative Supply

  Managing the complexities of today’s supply chain begins with transforming relationships that are historically transactional to those that drive suppliers to become value-add partners working toward shared goals with their customers.

• Safely Transporting Medicines To Patients

  Do pharmaceutical companies underestimate the challenges of transportation throughout the supply chain? There are many pain points when it comes to sending a therapy from A to B, but with the right collaborations in place, these can be mitigated.

• The Need For Digital Networks To Support Cell And Gene Therapies

  Cell and gene therapies have a level of complexity from a supply chain perspective that needs new approaches, including a high level of information sharing and integration. This topic was covered from different perspectives at two recent conferences.

• Digitization Of The Supply Chain: Challenges In Scaling Up Cell & Gene Therapy

  This white paper discusses the unique biopharmaceutical supply chain challenges of Cell & Gene therapy logistics and recommends forward-thinking solutions to address them. Successfully overcoming these logistics challenges is essential in order to scale up C&G therapies to treat large numbers of patients worldwide.

• Does Blockchain Make Sense For The Cell & Gene Therapy Supply Chain?

  Understanding the impact and requirements for a clearly defined supply chain strategy and implementing this into the complex environment of cell and gene therapies is not a simple task. It requires dedication and participation from all the stakeholders across the development-to-delivery life cycle. All the details need to be defined, simulation models developed, and risk assessed — and remediation plans put in place. 

• Securing Bioprocess Film Supply

  Learn how a partnership built on technical expertise and trust is helping to secure the supply of a single-use film built for bioprocessing.

• Catalent Biologics: Delivering Therapies To Market Faster

  Catalent Biologics is an integrated partner with expertise to get a biologic to market faster. The company has the passion to help its partners accelerate, simplify and de-risk their biologic therapies -- from development and manufacturing, to fill/finish, clinical supply and commercial launch.

• Catalent Clinical Supply Services

  Whether you have a large, complex global study or need a small, regional solution, we can reliably supply your clinical trial anywhere in the world. From Phase I to Phase III and beyond, we are the catalyst for your success.

• Transforming Next-Gen Therapy Supply Chains Into Patient-Connected Value Chains

  Cell, gene, and other emerging therapies are distinctly different from traditional biopharma products. Every lot is for a named patient or small population of patients, and that lot drives direct uplift on the bottom line. Traditional supply chain management does not necessarily create patient value in emerging therapy value chains. Operations should be the backbone of a distribution model that delivers these products efficiently and effectively over the last few yards.

• Managing Risks To Time Critical Product Imports At Clinical Supply Depots

  Global regulatory standards for clinical trials are, simply put, complex. In this case study, learn how one company worked with its partner to overcome the challenge of a protocol based in the US, an investigational medical product (IMP) approved in the EU, and varying QP (qualified person) rules from country to country, to conduct their clinical trial in Isreal.